Advanced search
1 file | 1.10 MB Add to list

The effect of selenium and zinc on CD4(+) count and opportunistic infections in HIV/AIDS patients : a randomized double blind trial

Author
Organization
Abstract
Objectives: We assessed the effect of selenium and zinc supplementation on CD4 cell count and the risk of developing opportunistic infections. Methods: In a double blind clinical trial, 146 HIV(+) patients receiving combination antiretroviral therapy with CD4(+) >200/cubic millimeter were screened for comorbidities and opportunistic infections, and randomized to receive daily selenium (200 mu g), zinc (50 mg) or placebo for 6 months, before a 3-month follow-up period. CD4 cell counts were measured in the 3(th), 6(th) and 9(th) months. The serum selenium and zinc were measured in the 6(th) month. The incidence of opportunistic infection was assessed monthly for 6 months and at the end of the 9(th) month. Results: The final incidence of supplement deficiency for placebo, zinc and selenium were 46.7%, 44.7% and 50.0%, respectively. Overall compliance with supplementation was 99.42%. Although the changes from baseline were not statistically significant, zinc supplementation was significantly associated with reduced risk of opportunistic infections. Conclusion: Development of the opportunistic infections after zinc supplementation significantly decreased; however, significant improvement in CD4 count was not observed in this group.
Keywords
Selenium, zinc, HIV, AIDS, lymphocyte count, IMMUNODEFICIENCY-VIRUS TYPE-1, ACTIVE ANTIRETROVIRAL THERAPY, MICRONUTRIENT SUPPLEMENTATION, HIV-1 INFECTION, SERUM SELENIUM, MORTALITY, RISK, INDIVIDUALS, ACTIVATION, NUTRITION

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.10 MB

Citation

Please use this url to cite or link to this publication:

MLA
Hadadi, Azar, et al. “The Effect of Selenium and Zinc on CD4(+) Count and Opportunistic Infections in HIV/AIDS Patients : A Randomized Double Blind Trial.” ACTA CLINICA BELGICA, 2020.
APA
Hadadi, A., Ostovar, A., Edalat Noor, B., Rasoolinejad, M., Haji Abdolbaghi, M., Yousefi, S., … Safari, N. (2020). The effect of selenium and zinc on CD4(+) count and opportunistic infections in HIV/AIDS patients : a randomized double blind trial. ACTA CLINICA BELGICA.
Chicago author-date
Hadadi, Azar, Afshin Ostovar, Behnaz Edalat Noor, Mehrnaz Rasoolinejad, Mahboobeh Haji Abdolbaghi, Sahar Yousefi, Hossein Khalili, et al. 2020. “The Effect of Selenium and Zinc on CD4(+) Count and Opportunistic Infections in HIV/AIDS Patients : A Randomized Double Blind Trial.” ACTA CLINICA BELGICA.
Chicago author-date (all authors)
Hadadi, Azar, Afshin Ostovar, Behnaz Edalat Noor, Mehrnaz Rasoolinejad, Mahboobeh Haji Abdolbaghi, Sahar Yousefi, Hossein Khalili, Gita Manshoori, Patricia Khashayar, Zahra Alipour, and Narges Safari. 2020. “The Effect of Selenium and Zinc on CD4(+) Count and Opportunistic Infections in HIV/AIDS Patients : A Randomized Double Blind Trial.” ACTA CLINICA BELGICA.
Vancouver
1.
Hadadi A, Ostovar A, Edalat Noor B, Rasoolinejad M, Haji Abdolbaghi M, Yousefi S, et al. The effect of selenium and zinc on CD4(+) count and opportunistic infections in HIV/AIDS patients : a randomized double blind trial. ACTA CLINICA BELGICA. 2020;
IEEE
[1]
A. Hadadi et al., “The effect of selenium and zinc on CD4(+) count and opportunistic infections in HIV/AIDS patients : a randomized double blind trial,” ACTA CLINICA BELGICA, 2020.
@article{8611114,
  abstract     = {Objectives: We assessed the effect of selenium and zinc supplementation on CD4 cell count and the risk of developing opportunistic infections. Methods: In a double blind clinical trial, 146 HIV(+) patients receiving combination antiretroviral therapy with CD4(+) >200/cubic millimeter were screened for comorbidities and opportunistic infections, and randomized to receive daily selenium (200 mu g), zinc (50 mg) or placebo for 6 months, before a 3-month follow-up period. CD4 cell counts were measured in the 3(th), 6(th) and 9(th) months. The serum selenium and zinc were measured in the 6(th) month. The incidence of opportunistic infection was assessed monthly for 6 months and at the end of the 9(th) month. Results: The final incidence of supplement deficiency for placebo, zinc and selenium were 46.7%, 44.7% and 50.0%, respectively. Overall compliance with supplementation was 99.42%. Although the changes from baseline were not statistically significant, zinc supplementation was significantly associated with reduced risk of opportunistic infections. Conclusion: Development of the opportunistic infections after zinc supplementation significantly decreased; however, significant improvement in CD4 count was not observed in this group.},
  author       = {Hadadi, Azar and Ostovar, Afshin and Edalat Noor, Behnaz and Rasoolinejad, Mehrnaz and Haji Abdolbaghi, Mahboobeh and Yousefi, Sahar and Khalili, Hossein and Manshoori, Gita and Khashayar, Patricia and Alipour, Zahra and Safari, Narges},
  issn         = {1784-3286},
  journal      = {ACTA CLINICA BELGICA},
  keywords     = {Selenium,zinc,HIV,AIDS,lymphocyte count,IMMUNODEFICIENCY-VIRUS TYPE-1,ACTIVE ANTIRETROVIRAL THERAPY,MICRONUTRIENT SUPPLEMENTATION,HIV-1 INFECTION,SERUM SELENIUM,MORTALITY,RISK,INDIVIDUALS,ACTIVATION,NUTRITION},
  language     = {eng},
  title        = {The effect of selenium and zinc on CD4(+) count and opportunistic infections in HIV/AIDS patients : a randomized double blind trial},
  url          = {http://dx.doi.org/10.1080/17843286.2019.1590023},
  year         = {2020},
}

Altmetric
View in Altmetric
Web of Science
Times cited: